Literature DB >> 12849527

Dosing in phase II trial of Alzheimer's vaccine suspended.

Kathryn Senior.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12849527     DOI： 10.1016/s1474-4422(02)00023-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  23 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 2.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.

Authors:  Frédérique Bard; Robin Barbour; Catherine Cannon; Robert Carretto; Michael Fox; Dora Games; Teresa Guido; Kathleen Hoenow; Kang Hu; Kelly Johnson-Wood; Karen Khan; Dora Kholodenko; Celeste Lee; Mike Lee; Ruth Motter; Minh Nguyen; Amanda Reed; Dale Schenk; Pearl Tang; Nicki Vasquez; Peter Seubert; Ted Yednock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-03       Impact factor: 11.205

Review 4.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

Review 5.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

6.  Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.

Authors:  Anahit Ghochikyan; Mikayel Mkrtichyan; Irina Petrushina; Nina Movsesyan; Adrine Karapetyan; David H Cribbs; Michael G Agadjanyan
Journal:  Vaccine       Date:  2005-12-05       Impact factor: 3.641

Review 7.  Antibody Therapeutics Targeting Aβ and Tau.

Authors:  Gilbert Gallardo; David M Holtzman
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

Review 8.  Peripheral inflammation in neurodegeneration.

Authors:  Ulrike Träger; Sarah J Tabrizi
Journal:  J Mol Med (Berl)       Date:  2013-04-02       Impact factor: 4.599

Review 9.  Protein aggregation diseases: pathogenicity and therapeutic perspectives.

Authors:  Adriano Aguzzi; Tracy O'Connor
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 10.  Immunotherapy for Alzheimer's disease.

Authors:  David S Gelinas; Kevin DaSilva; Daniela Fenili; Peter St George-Hyslop; Joanne McLaurin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.